σ2 receptors regulate changes in sphingolipid levels in breast tumor cells

被引:72
作者
Crawford, KW
Coop, A
Bowen, WD
机构
[1] NIDDK, Unit Receptor Biochem & Pharmacol, Med Chem Lab, NIH, Bethesda, MD 20892 USA
[2] Howard Univ, Coll Med, Dept Pharmacol, Washington, DC 20059 USA
[3] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
关键词
sigma receptor; ceramide; apoptosis;
D O I
10.1016/S0014-2999(02)01581-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
sigma(2) Receptors induce apoptosis in various cell types. The sphingolipid, ceramide as well as the sphingoid bases are involved in cell proliferation. Sphingolipids of MCF-7/Adr- and T47D breast tumor cells were metabolically radiolabeled. The sigma(2) receptor agonists (+)-1R,5R-E-8-(3,4-dichlorobenzylidene)-5-(3-hydroxyphenyl)-2-methylmorphan-7-one (CB-184) and 1S,2R-(-)-cis-N-[2-(3,4-dichlorophenyl) ethyl]-N-methyl-2-(1-pyrrolidinyl)-cyclohexylamine (BD737) caused dose-dependent increases in [H-3]ceramide, with concomitant decreases in [H-3]sphingomyelin. Both effects were attenuated by the novel sigma(2) receptor antagonist, N-phenethylpiperidine oxalate (AC927). sigma(2) Receptors may produce effects on cell growth and apoptosis by regulating the sphingolipid pathway. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:207 / 209
页数:3
相关论文
共 8 条
[1]   CB-64D AND CB-184 - LIGANDS WITH HIGH SIGMA(2) RECEPTOR AFFINITY AND SUBTYPE SELECTIVITY [J].
BOWEN, WD ;
BERTHA, CM ;
VILNER, BJ ;
RICE, KC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 278 (03) :257-260
[2]  
Crawford KW, 2002, CANCER RES, V62, P313
[3]   Regulation of ceramide production and apoptosis [J].
Kolesnick, RN ;
Krönke, M .
ANNUAL REVIEW OF PHYSIOLOGY, 1998, 60 :643-665
[4]   Functions of a new family of sphingosine-1-phosphate receptors [J].
Spiegel, S ;
Milstien, S .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1484 (2-3) :107-116
[5]  
Vilner B. J., 1999, Society for Neuroscience Abstracts, V25, P1475
[6]  
VILNER BJ, 1995, J NEUROSCI, V15, P117
[7]  
Vilner BJ, 2000, J PHARMACOL EXP THER, V292, P900
[8]  
VILNER BJ, 1995, CANCER RES, V55, P408